AR049941A1 - Derivados de hexafluorisopropanol - Google Patents

Derivados de hexafluorisopropanol

Info

Publication number
AR049941A1
AR049941A1 ARP050102607A ARP050102607A AR049941A1 AR 049941 A1 AR049941 A1 AR 049941A1 AR P050102607 A ARP050102607 A AR P050102607A AR P050102607 A ARP050102607 A AR P050102607A AR 049941 A1 AR049941 A1 AR 049941A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
alkyl
alkoxy
heterocyclyl
aryl
Prior art date
Application number
ARP050102607A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970254&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049941(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR049941A1 publication Critical patent/AR049941A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Estos compuestos se fijan sobre el LXR-alfa y el LXR-beta y pueden utilizarse como medicamentos. Reivindicacion 1: Compuestos de formula (1), en la que: R1 es hidrogeno, halogeno o alquilo inferior; R2 es alquilo inferior, fluoroalquilo inferior, cicloalquil-alquilo inferior o heterociclil-alquilo inferior; R3 es hidrogeno, alquilo inferior, cicloalquilo, arilo o heterociclilo; R4 es hidrogeno, hidroxi, alcoxi inferior, aril-alcoxi inferior o heterociclil-alcoxi inferior; R5 es hidrogeno, alquilo inferior, arilo o heterociclilo; R6 es arilo, heterociclilo; o una formula (2); R7 es alquilo inferior o fluoroalquilo inferior; R8 es fenilo que está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo formado por hidroxi, amino, halogeno, alquilo inferior, fluoroalquilo inferior, hidroxi-alquilo inferior, R9-O-C(O)-, R10R11NC(O)-, R12-O-C(O)-alquilo inferior, R13-O-C(O)-hidroxi-alquilo inferior, R14R15NC(O)-alquilo inferior, R16R17NC(O)-hidroxi-alquilo inferior, alcoxi inferior, aril-alcoxi inferior, R18-O-C(O)-alcoxi inferior y R19R20NC(O)-alcoxi inferior; R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 y R20 con independencia entre sí son hidrogeno o alquilo inferior; L es un enlace simple, alquileno inferior o alquenileno inferior; m es un numero de 0 a 3; n es 0 o 1; y sales y ésteres farmacéuticamente aceptables de los mismos.
ARP050102607A 2004-06-28 2005-06-24 Derivados de hexafluorisopropanol AR049941A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04103006 2004-06-28

Publications (1)

Publication Number Publication Date
AR049941A1 true AR049941A1 (es) 2006-09-13

Family

ID=34970254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102607A AR049941A1 (es) 2004-06-28 2005-06-24 Derivados de hexafluorisopropanol

Country Status (12)

Country Link
US (4) US7259178B2 (es)
EP (1) EP1763502A1 (es)
JP (1) JP4809338B2 (es)
CN (1) CN1972897A (es)
AR (1) AR049941A1 (es)
AU (1) AU2005256394B2 (es)
BR (1) BRPI0512699A (es)
CA (1) CA2571356A1 (es)
MX (1) MXPA06014807A (es)
RU (1) RU2389718C2 (es)
TW (1) TW200626527A (es)
WO (1) WO2006000323A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972897A (zh) * 2004-06-28 2007-05-30 霍夫曼-拉罗奇有限公司 新型六氟异丙醇衍生物
CN101087754B (zh) * 2004-12-22 2012-01-18 霍夫曼-拉罗奇有限公司 环己烷衍生物
US7928160B2 (en) * 2005-08-25 2011-04-19 Ppg Industries Ohio, Inc. Coating composition of polyurea, polyurethane and flame retardant
EP2142533B1 (en) * 2007-03-30 2011-11-16 F. Hoffmann-La Roche AG Imidazolidinone derivatives
CN101970479A (zh) * 2008-03-17 2011-02-09 弗·哈夫曼-拉罗切有限公司 Lxr配体结合结构域(lxr lbd)晶体
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
FR2935380B1 (fr) * 2008-08-29 2010-09-10 Galderma Res & Dev Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
US20120115912A1 (en) * 2009-07-10 2012-05-10 Landreth Gary E Rxr agonist compounds and methods
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CN109789129B (zh) * 2016-07-12 2022-04-29 延世大学校产学协力团 自噬改良材料及其用途
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
US20220257596A1 (en) 2019-07-15 2022-08-18 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075339A (en) * 1989-07-28 1991-12-24 Du Pont Merck Pharmaceutical Company Benzylketone phospholipase A2 inhibitors
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
WO2003090869A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
AU2003223684A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
MXPA04011691A (es) * 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
CN1972897A (zh) * 2004-06-28 2007-05-30 霍夫曼-拉罗奇有限公司 新型六氟异丙醇衍生物

Also Published As

Publication number Publication date
TW200626527A (en) 2006-08-01
US7259178B2 (en) 2007-08-21
JP2008504313A (ja) 2008-02-14
WO2006000323A1 (en) 2006-01-05
AU2005256394A1 (en) 2006-01-05
RU2389718C2 (ru) 2010-05-20
US20070213377A1 (en) 2007-09-13
JP4809338B2 (ja) 2011-11-09
RU2007103304A (ru) 2008-08-10
US20100004297A1 (en) 2010-01-07
US20060004068A1 (en) 2006-01-05
CA2571356A1 (en) 2006-01-05
BRPI0512699A (pt) 2008-04-01
MXPA06014807A (es) 2007-02-12
CN1972897A (zh) 2007-05-30
EP1763502A1 (en) 2007-03-21
US7608721B2 (en) 2009-10-27
AU2005256394B2 (en) 2008-07-17
US20080096937A1 (en) 2008-04-24
US7897815B2 (en) 2011-03-01

Similar Documents

Publication Publication Date Title
AR049941A1 (es) Derivados de hexafluorisopropanol
AR065863A1 (es) Derivados de imidazolidinona
AR054870A1 (es) Tetrahidrobenzoxazinas como estabilizadores
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
CO5150228A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
ES2330313T3 (es) Derivados de tiofeno como agentes antivirales contra infeccion por flavivirus.
ECSP067124A (es) Inhibidores de cetp
AR067904A1 (es) Derivados de piperazina-amida
CO5721001A2 (es) Derivados sustituidos de morfolina y tiomorfolina
AR025225A1 (es) Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas
AR073990A1 (es) Derivados de fenilamida y piridilamida
AR047848A1 (es) Analogos de rifamicina y composiciones farmaceuticas que los contienen.
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR072969A1 (es) Derivados de ciclohexilamida, composiciones farmaceuticas y usos como antagonistas del receptor del factor de liberacion de corticotropina (crf - 1)
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
GT200100254A (es) Nuevas imidazotriazinonas sustituidas
CR20160236A (es) Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos
AR049324A1 (es) Derivados de hidroxi-6-fenilfenantridinas amido sustituidas. composiciones farmacéuticas.
AR013153A1 (es) Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.
PE20011089A1 (es) Tioamidas de oxazolidinona con sustituyentes de piperazin-amida
AR073262A1 (es) Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal